NVO catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
- Completion LockedPhase 4NCT05195944Semaglutide vs SitagliptinUniversity Health Network, Toronto · Liver Transplant; ComplicationsActive, not recruitingNVOCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT06240208Physical Inactivity and Appetite RegulationCopenhagen University Hospital, Rigshospitalet · OverweightRecruitingNVOCollaborator
- Enrollment
- Locked
- Primary completion
- May 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT06442644Live Music in the Intensive Care UnitAarhus University Hospital · StressNot yet recruitingNVOCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 2025Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT04682145Adverse Event Data Collection From the EUHASS Registry on Turoctocog Alfa PegolNovo Nordisk A/S · Haemophilia AEnrolling by invitationNVOLead
- Enrollment
- Locked
- Primary completion
- Dec 1, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT05726227A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose WeightNovo Nordisk A/S · ObesityActive, not recruitingNVOLead
- Enrollment
- Locked
- Primary completion
- Oct 15, 2025Actual
- Interventions
- Locked
- Completion LockedNo phase registeredNCT06137261Screening Adults With Obesity to Reduce Heart Failure EventsFranciscus Gasthuis · ObesityActive, not recruitingNVOCollaboratorSNYCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 8, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT07769489Study to Assess Tolerability of Injecting Larger Volumes (2-5 mL) Subcutaneously at Different Rates: Participant Experience and AcceptanceNovo Nordisk A/S · Healthy ParticipantsRecruitingNVOLead
- Enrollment
- Locked
- Primary completion
- Dec 9, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT07184632A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help People Living With Overweight or ObesityNovo Nordisk A/S · OverweightActive, not recruitingNVOLead
- Enrollment
- Locked
- Primary completion
- Dec 14, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT03878446A Research Study in Children Born Small and Who Stayed Small. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a DayNovo Nordisk A/S · Short Stature Children Born Small for Gestational Age (SGA)Active, not recruitingNVOLead
- Enrollment
- Locked
- Primary completion
- May 5, 2021Actual
- Interventions
- Locked
- Completion LockedNo phase registeredNCT07653139Patient Preferences in Treatment of Haemophilia A With and Without Inhibitors: a Discrete Choice Experiment in GermanyNovo Nordisk A/S · Haemophilia AEnrolling by invitationNVOLead
- Enrollment
- Locked
- Primary completion
- Dec 26, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT07739901Korean Real-world Study on MASLD/MASH Outcomes.Novo Nordisk A/S · MASLD/MASHActive, not recruitingNVOLead
- Enrollment
- Locked
- Primary completion
- Dec 28, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT05230550Post-Marketing Surveillance (Special Use-results Surveillance on Long-term Use) With Sogroya®Novo Nordisk A/S · Adult Growth Hormone DeficiencyActive, not recruitingNVOLead
- Enrollment
- Locked
- Primary completion
- Dec 31, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 4NCT05780905Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 DiabetesUniversity of Washington · Diabetes Mellitus, Type 2RecruitingNVOCollaborator
- Enrollment
- Locked
- Primary completion
- Mar 31, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT06109935Special Use-results Surveillance on Long Term Use of Sogroya® in Children With Short Stature Due to Growth Hormone Deficiency Where...Novo Nordisk A/S · Growth Hormone Deficiency in ChildrenEnrolling by invitationNVOLead
- Enrollment
- Locked
- Primary completion
- Jul 31, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT07656454A Study Understanding How Much CDR132L Enters the Bloodstream After Injection Under the Skin Compared to Injection Into a Vein in...Novo Nordisk A/S · Healthy VolunteersRecruitingNVOLead
- Enrollment
- Locked
- Primary completion
- Dec 31, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT07713901Database Linkage Study to Evaluate the Risk of Medullary Thyroid CarcinomaNovo Nordisk A/S · Medullary Thyroid CarcinomaEnrolling by invitationNVOLead
- Enrollment
- Locked
- Primary completion
- Dec 31, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT07225816Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in...Novo Nordisk A/S · ObesityRecruitingNVOLead
- Enrollment
- Locked
- Primary completion
- Dec 13, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT06200207A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and InflammationNovo Nordisk A/S · Heart FailureActive, not recruitingNVOLead
- Enrollment
- Locked
- Primary completion
- Oct 1, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT07160816A Research Study to See How Insulin Icodec Helps People With Type 1 Diabetes Control Their Blood SugarNovo Nordisk A/S · Diabetes Mellitus, Type 1Active, not recruitingNVOLead
- Enrollment
- Locked
- Primary completion
- Jan 20, 2027Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT07437079A Study to See How Safe a New Medicine (NNC6989-0001) is in Healthy People Living With Overweight or ObesityNovo Nordisk A/S · OverweightRecruitingNVOLead
- Enrollment
- Locked
- Primary completion
- Jan 21, 2027Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT07411560A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are...Novo Nordisk A/S · OverweightRecruitingNVOLead
- Enrollment
- Locked
- Primary completion
- Jan 26, 2027Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT06118281ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart AttackNovo Nordisk A/S · Cardiovascular RiskActive, not recruitingNVOLead
- Enrollment
- Locked
- Primary completion
- Jan 29, 2027Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT07566390A Research Study Investigating How a New Medicine NNC0113-5840 Works in People With Overweight or ObesityNovo Nordisk A/S · ObesityRecruitingNVOLead
- Enrollment
- Locked
- Primary completion
- Jan 31, 2027Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT06449625Semaglutide in Auto-HSCTKlaus Gottlob Müller · Intestinal MucositisNot yet recruitingNVOCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 31, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT07220564A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia ANovo Nordisk A/S · Haemophilia ARecruitingNVOLead
- Enrollment
- Locked
- Primary completion
- Feb 5, 2027Sponsor estimate
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 2 more in this window; the full list is part of TrialScanner.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.